Bulletin
Investor Alert

Enanta Pharmaceuticals Inc.

NAS: ENTA

GO
/marketstate/country/us

After Hours

/zigman2/quotes/209139157/composite

$

24.89

Change

0.00 0.00%

Volume

Volume 2,710

May 26, 2023, 4:07 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/209139157/composite

Previous close

$ 24.86

$ 24.89

Change

+0.03 +0.12%

Day low

Day high

$24.41

$25.03

Open
Open: 24.82

52 week low

52 week high

$23.03

$76.36

Open

Market cap

$524.07M

Average volume

199,594

P/E ratio

N/A

Rev. per Employee

$507,350

EPS

-5.98

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/enta

MarketWatch News on ENTA

  1. Enanta Pharmaceuticals upgraded to outperform from in line at Evercore ISI

    6:02 a.m. July 6, 2022

    - Tomi Kilgore

  2. Enanta Pharmaceuticals price target cut to $74 from $89 at JPMorgan, stock rated neutral

    8:12 a.m. March 23, 2022

    - Tonya Garcia

  3. Enanta Pharmaceuticals upgraded to neutral from underweight at J.P. Morgan

    8:17 a.m. Jan. 29, 2021

    - Tomi Kilgore

  4. Enanta Pharmaceuticals downgraded to perform from outperform at Oppenheimer

    7:21 a.m. Aug. 8, 2018

    - Tomi Kilgore

  5. Enanta Pharmaceuticals downgraded to neutral from overweight at J.P. Morgan

    8:55 a.m. Feb. 8, 2018

    - Tomi Kilgore

  6. Enanta Pharmaceuticals downgraded to sector perform vs outperform at RBC

    8:53 a.m. Jan. 2, 2018

    - Ciara Linnane

  7. These 55 stocks have at least doubled since Trump was elected

    4:04 p.m. Dec. 19, 2017

    - Philip van Doorn

  8. Gilead Sciences: Still Dominating Hepatitis C But…

    3:24 p.m. Aug. 17, 2016

    - Barrons Blogs

  9. Enanta Pharmaceuticals upgraded to overweight from equal weight at Barclays

    12:08 p.m. Oct. 23, 2015

    - Tomi Kilgore

  10. Health-Care Firestorm Engulfs Hospitals, AbbVie

    9:52 a.m. Oct. 23, 2015

    - Barrons Blogs

  11. AbbVie’s Pain is Gilead’s Gain, But is It an Overreaction?

    4:19 p.m. Oct. 22, 2015

    - Barrons Blogs

  12. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/enta

Other News on ENTA

  1. 10-Q: ENANTA PHARMACEUTICALS INC

    5:24 p.m. May 9, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-K: ENANTA PHARMACEUTICALS INC

    5:15 p.m. Nov. 23, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates

    8:45 a.m. Nov. 1, 2022

    - Zacks.com

  4. Top 5 2nd Quarter Trades of Krensavage Asset Management, LLC

    7:00 p.m. Aug. 16, 2022

    - GuruFocus.com

  5. Top 5 2nd Quarter Trades of Stonepine Capital Management, LLC

    1:00 a.m. Aug. 15, 2022

    - GuruFocus.com

  6. 10-Q: ENANTA PHARMACEUTICALS INC

    4:15 p.m. Aug. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

/news/pressrelease/company/us/enta

Press Releases on ENTA

  1. Loading more headlines...

Rates »

Link to MarketWatch's Slice.